<DOC>
	<DOCNO>NCT00436449</DOCNO>
	<brief_summary>This multi-centre , double-blind , within-subject , placebo control randomised trial female subject . All subject undergo bilateral breast augmentation surgery . Immediately follow surgery , subject receive 100µl contain 50ng 200ng RN1001 per linear centimetre intradermally margin one breast wound , 100µl placebo solution per linear centimetre intradermally margin breast wound . The allocation treatment wound ( left right ) randomise double blind .</brief_summary>
	<brief_title>RN1001 ( Avotermin ) Scar Improvement Following Breast Augmentation</brief_title>
	<detailed_description />
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Female subject 18 60 year age undergoing bilateral breast augmentation inframammary fold incision give write informed consent . Weight 50 150kg body mass index within permit range height use Quetelet 's indexweight ( kg ) /height² ( ) . The permitted index 1555 . Subjects child bear potential use method ( ) contraception acceptable Investigator agree least screening visit 1 month post surgery . Subjects implant position use breast ; implant place submammary subpectoral pocket . Subjects type size implant use breast . Subjects , opinion Investigator , clinically acceptable result laboratory test specify trial protocol . All laboratory test must perform within 28 day prior Day 0 . Subjects significant breast asymmetry may produce different length site wound , different postoperative tension wound . Subjects direct question physical examination history evidence hypertrophic keloid scarring . Subjects surgery area incise within one year Day 0 . Subjects personal history bleed disorder . Subjects history breast malignancy . Subjects skin disorder chronic currently active Investigator considers adversely affect heal acute wound involve area examine trial . Subjects direct question and/or physical examination , evidence past present clinically significant medical condition would impair wound heal . Subjects history clinically significant hypersensitivity drug surgical dressing use trial . Subjects take , take , investigational drug include RN1001 within 3 month prior screen visit . Subjects take regular , continuous , oral corticosteroid therapy . Subjects undergoing investigation change management exist medical condition . Subjects become pregnant include Day 0 lactating . Subjects diseases condition could opinion Investigator interfere assessment safety , tolerability efficacy . In opinion Investigator , subject likely complete trial ever reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>